No quarterly revenue total was found in AN2 Therapeutics, Inc.'s SEC filings.
AN2 Therapeutics, Inc. (ANTX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-8.19M
-26.7% vs year-ago quarter
Operating cash flow
$-7.00M
+7.9% vs year-ago quarter
Free cash flow
—
EPS
$-0.18
+14.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
37.74M
+38.1% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Menlo Park, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1880438
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$8.9M | -$10.6M | -$9.3M | -$10.0M | -$7.2M |
| Net income | -$8.2M | -$10.0M | -$8.7M | -$9.4M | -$6.5M |
| Diluted EPS | -$0.18 | -$0.29 | -$0.29 | -$0.31 | -$0.21 |
| Operating cash flow | -$7.0M | -$12.1M | -$5.2M | -$6.4M | -$7.6M |
| Total assets | $81.7M | $87.5M | $62.0M | $67.2M | $75.8M |
| Total liabilities | $5.8M | $5.7M | $8.9M | $6.9M | $7.0M |
| Stockholders' equity | $75.9M | $81.8M | $53.1M | $60.4M | $68.8M |
| Cash and investments | $79.9M | $85.3M | $60.0M | $65.1M | $71.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 3, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
All 384 AN2 Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.